Taiwan · Delayed Price · Currency is TWD Formosa Pharmaceuticals Company Description
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan.
It is involved in developing APP13007 that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-0110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections.
The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer.
It has a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutic.
The company was founded in 2010 and is headquartered in Taipei City, Taiwan.
| Country | Taiwan |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Erick Co |
Contact Details
Address: No. 57, Fuxing North Road Taipei, 105 Taiwan | |
| Phone | 886 2 2755 7659 |
| Website | formosapharma.com |
Stock Details
| Ticker Symbol | 6838 |
| Exchange | Taiwan Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Erick Co Ph.D. | President and Chief Executive Officer |
| Nai Hsien Tsao | Director of Finance and Chief Financial Officer |
| Helen Liu | Manager of Legal and Corporate Communications |
| Ching Cheng Wei M.P.H. | Chief Business and Strategy Officer |